A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy
Terminated · Not applicable · NCT06015295
Conditions: Brain Metastases
At a glance
- Research payments reported, 2025
- $5,166
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 3
About the trial
- Sponsor
- M.D. Anderson Cancer Center (with Blue Earth Diagnostics)
- Tested
- 18F-Fluciclovine (Axumin) (diagnostic_test), Pet Scan (diagnostic_test)
- Dates
- Started 2024-11-07; completion 2026-09-17
- Results posted
- Not yet
To learn if 18F-Fluciclovine (Axumin) PET-CT scans can be used to better detect brain metastatic lesions in patients who are receiving immunotherapy.
From ClinicalTrials.gov, last updated 2026-09-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Blue Earth Diagnostics reported $5,166 in research payments for this study in 2025 (1 payments).
Products named: Axumin
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $5,166
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.